Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-136438

Published: 2020

Journal Articles

Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors

Sherly Mardiana, PhD, Olga Shestova, PhD, Marco Ruella, MD, Saar Gill, MD PhD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-140092

Published: 2020

Journal Articles

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

Elise A. Chong, MD, Emeline R. Chong, Daniel J. Landsburg, MD, James N. Gerson, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Stefan K. Barta, MDMRCP,MS, Alfred L. Garfall, MD, Elizabeth Weber, BSN, RN, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143348

Published: 2020

Journal Articles

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-136860

Published: 2020

Journal Articles

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Jakub Svoboda, MD, Stefan K. Barta, MDMRCP,MS, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Wei-Ting Hwang, PhD, Grace Delp, Brittany Amundsen, Hatcher J. Ballard, BS, James N. Gerson, MD, Elise A. Chong, MD, Mitchell E. Hughes, PharmD, Steven A. Emanuel, Marco Ruella, MD, Stephen J. Schuster, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140507

Published: 2020

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood (2019) 134 (Supplement_1): 247.

https://doi.org/10.1182/blood-2019-131024

Published: 2019

Journal Articles

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Sunita Dwivedy Nasta, MD, Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Daniel J. Landsburg, MD, Elise A. Chong, MD, Stefan K. Barta, MD MRCP, MS, Noelle V. Frey, MD, James N. Gerson, MD, Amit Maity, MD PhD, John Plastaras, MD, David L. Porter, MD, Marco Ruella, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 4108.

https://doi.org/10.1182/blood-2019-131399

Published: 2019

Journal Articles

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

Sunita Dwivedy Nasta, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Elise A. Chong, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Daniel J. Landsburg, MD, Meredith I LaRose, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Marco Ruella, MD, Noelle V. Frey, MD, Stephen J. Schuster, MD, David L. Porter, MD

Blood (2019) 134 (Supplement_1): 3240.

https://doi.org/10.1182/blood-2019-130650

Published: 2019

Journal Articles

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Elise A. Chong, MD, Meredith I LaRose, MD, Steven M. Bair, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elizabeth Weber, BSN, RN, Chase Walling, BS, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 1606.

https://doi.org/10.1182/blood-2019-131482

Published: 2019

Journal Articles

Primary Mediastinal B-Cell Lymphoma: Evaluation of Clinicopathologic Diagnosis Compared to Gene Expression Based Diagnosis in a Clinical Trial with CD30+ B-Cell Lymphomas

Jakub Svoboda, MD, Steven M. Bair, MD, Christian Steidl, MD, Marco Ruella, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stefan Klaus Barta, MD MRCP, MS, M. Reza Nejati, MD, James Nathan Gerson, MD, Lauren Elizabeth Strelec, BA, Matthew R. Youngman, BS, Elise A. Chong, MD, Olga Kutovaya, PhD, Stacy Hung, Agata M. Bogusz, MD PhD, Megan S. Lim, MD, PhD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 2959.

https://doi.org/10.1182/blood-2018-99-115024

Published: 2018

Journal Articles

CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis

Nathan Singh, MD, Olga Shestova, PhD, Katharina Hayer, Albert Hong, Pranali Ravikumar, MS, Atushi Hoshino, MD PhD, Ophir Shalem, PhD, Matthew D. Weitzman, PhD, Carl H June, MD, Saar I. Gill, MDPhD, Marco Ruella, MD

Blood (2018) 132 (Supplement 1): 698.

https://doi.org/10.1182/blood-2018-99-117328

Published: 2018

Journal Articles

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Nicole Winchell, Ellen Napier, NP, Anthony R. Mato, MD MSCE, J. Joseph Melenhorst, PhD, Marco Ruella, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2018-99-119502

Published: 2018

Journal Articles

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Marco Ruella, MD, Shannon L Maude, MD PhD, Boris Engels, PhD, David M. Barrett, Noelle Frey, MD, Katherine T Marcucci, PhD, Olga Shestova, PhD, Nathan Singh, MD, Jessica Perazzelli, PhD, David A Christian, PhD, Dana Haagen, BS, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, David L Porter, MD, Carl H June, MD, Stephan A Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 807.

https://doi.org/10.1182/blood.V130.Suppl_1.807.807

Published: 2017

Journal Articles

A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells

Marco Ruella, MD, David M. Barrett, Olga Shestova, PhD, Jessica Perazzelli, PhD, Avery D. Posey, PhD, Miroslaw Kozlowski, PhD, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 4463.

https://doi.org/10.1182/blood.V130.Suppl_1.4463.4463

Published: 2017

Journal Articles

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Marco Ruella, MD, Michael Klichinsky, PharmD, Saad S Kenderian, MD, Olga Shestova, PhD, Amy Ziober, Michael D Feldman, MD, Mariusz A Wasik, MD, Carl H June, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 43.

https://doi.org/10.1182/blood.V128.22.43.43

Published: 2016

Journal Articles

Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR

Blood (2016) 128 (22): 281.

https://doi.org/10.1182/blood.V128.22.281.281

Published: 2016

Journal Articles

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Miriam Y Kim, MD, Saad S Kenderian, MD, Daniel Schreeder, MD PhD, Michael Klichinsky, PharmD, Miroslaw Kozlowski, PhD, Olga Shestova, PhD, Marco Ruella, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 1000.

https://doi.org/10.1182/blood.V128.22.1000.1000

Published: 2016

Journal Articles

Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, J. Joseph Melenhorst, PhD, Mariusz A Wasik, MD, Simon F. Lacey, PhD, Carl H June, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 2159.

https://doi.org/10.1182/blood.V128.22.2159.2159

Published: 2016

Journal Articles

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Miriam Y Kim, MD, Michael Klichinsky, PharmD, Fang Chen, PhD, Natalka Kengle, Simon Francis Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 652.

https://doi.org/10.1182/blood.V128.22.652.652

Published: 2016

NARROW

R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET

Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Primary Mediastinal B-Cell Lymphoma: Evaluation of Clinicopathologic Diagnosis Compared to Gene Expression Based Diagnosis in a Clinical Trial with CD30+ B-Cell Lymphomas

CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only